HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision allosteric therapeutics. The collaboration will utilize Atavistik's ...

Enriched with years of accumulated experience with its proprietary computation-based allosteric drug development technology and breakthrough innovation capabilities at Nutshell Therapeutics ...

Allosteric modulators bind to their target receptor outside of the active site, where the natural ligand and traditional drugs operate, and have emerged as a way to target receptors that have ...

About Eisbach Eisbach is at the forefront of precision oncology, developing allosteric drugs that selectively disrupt molecular machines vital for tumor genome reorganization. Combining genetic ...

HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural ...

Bollon, President and Co-Founder of Allosteric Bioscience, Inc. “We are very excited to be working with Dr. Barbara Slusher and her team on this critical program.” “At Johns Hopkins Drug ...

Allosteric modulators like GT-02287 are drugs that bind to a protein's surface, changing the formation of the protein's binding site. But biotechs working with this drug class have struggled to ...